This review focuses on the research progress of ADCs targeting non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), providing an in-depth analysis of their mechanisms of action, molecular design, and clinical efficacy, with particular emphasis on novel ADCs targeting HER2, TROP2, and DLL3.
Yi-Lin Zhao, Xiao-Ran Ma, Xiao-Zhen Liu et al.· Cancer Chemotherapy and Phar...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.